Medical/Pharmaceuticals
Everest Medicines Announces Interim Results for First Half of 2025
SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 a...
2025-08-29 07:52
2711
Hua Medicine Announces 2025 Interim Results
* Sales of HuaTangNing (华堂宁®) increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achie...
2025-08-28 17:58
2652
Futurise Lead RegTalk 2025: AI Medical Devices in Malaysia - Balancing Innovation and Safety
CYBERJAYA, Malaysia, Aug. 28, 2025 /PRNewswire/ -- Futurise Sdn Bhd (Futurise), in collaboration with the Medical Device Authority (MDA), hosted the latest edition of RegTalk at the Siemens Healthineers Experience Center, focusing on "AI Medical Devices inMalaysia – Balancing Innovation & Safety....
2025-08-28 15:01
2836
ACROBiosystems and DAAN Biotherapeutics Sign Strategic MOU for the Development of Precision Immuno-Oncology Therapeutics
SEOUL, South Korea, Aug. 28, 2025 /PRNewswire/ -- ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, announced that it has entered into a strategic Memorandum of Understanding (MOU) with DAAN Biotherapeutic...
2025-08-28 09:54
1598
AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector
HONG KONG, Aug. 28, 2025 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are ...
2025-08-28 07:45
1389
XtalPi Holdings Announces 2025 Interim Results
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Revenue surged 404% year over year to RMB 517 million in the first half of 2025. * Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. * XtalPi wa...
2025-08-27 22:26
2615
Neusoft Medical Systems Launches China's First Photon-Counting CT with NMPA Approval
SHENYANG, China, Aug. 27, 2025 /PRNewswire/ -- Neusoft Medical Systems today announced that its NeuViz P10 photon-counting CT has received market approval fromChina's National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved inChina, and the world's first w...
2025-08-27 21:03
1665
Fosun International: Total Revenue for the First Half of 2025 Reaches RMB87.28 Billion, Industrial Operation Profit Amounts to RMB3.15 Billion
HONG KONG, Aug. 27, 2025 /PRNewswire/ -- On 27 August, Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended30 June 2025. In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leverag...
2025-08-27 20:40
3435
Digital twin technology with AI to boost efficiency and reliability in pharmaceutical manufacturing
* Cambridge Advanced Research and Education in Singapore (CARES), the University of Cambridge's first overseas research centre, together with the A*STAR Institute for Infocomm Research (A*STAR I2R) has developed a digital twin platform that uses artificial intelligence (AI) and real-time plant ...
2025-08-27 13:00
1416
Crescom to Showcase Musculoskeletal AI Innovations at 26th Asian Musculoskeletal Society Annual Meeting
Company to present MediAI solution suite and strengthen partnerships for expansion across Southeast andEast Asia SEOUL, South Korea, Aug. 27, 2025 /PRNewswire/ -- Crescom, a leader in AI-powered musculoskeletal (MSK) image analysis software, announced its participation in the 26th Asian Musculos...
2025-08-27 09:00
1399
Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner
DENVER, Aug. 27, 2025 /PRNewswire/ -- Cerecin, a global biotech company focused on neurometabolism, is proud to announce its partnership with the NIHR HealthTech Research Centre (HRC) in Brain Health, joining a distinguished group of industry leaders including GE Healthcare, Novo Nordisk, Roche D...
2025-08-27 00:04
1361
ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA
At EURETINA 2025, ZEISS Medical Technology combines its diagnostic, surgical and digital technologies to support healthcare professionals in advancing retinal care: * IMPROVE PATHOLOGY DETECTION: Now CE mark approved, CIRRUS® PathFinderTM AI decision support tool streamlines OCT data review; I...
2025-08-26 20:00
1268
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
* Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais * This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches inMalaysia and Indi...
2025-08-26 14:29
1707
Basecare Medical (02170.HK) Gems Culture Medium Receives First Approval from NMPA, Advancing the Localization of Assisted Reproductive Fluids
SUZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Recently, Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has officially received registration approval from the National Medical Products Administration (NMPA)...
2025-08-26 11:47
1876
Fullerton Health Announces Strategic Investment by Mitsubishi Corporation
SINGAPORE, Aug. 26, 2025 /PRNewswire/ -- Fullerton Health Pte. Ltd. ("Fullerton Health" or the "Company"), a leading healthcare solutions provider operating in nine markets acrossAsia-Pacific, today announced that Mitsubishi Corporation has acquired a strategic minority stake in the Company. This...
2025-08-26 10:00
1846
Infinitus Named in Liaowang Institution's "Leading Transparent Factory Case Studies"
GUANGZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Amid the digital economy and shifting consumer expectations, "trust" has become a core driver of sustainable business growth. The "Transparent Factory • Building the Future with Trust — 2025 Trust Productivity High-End Dialogue" was held in Jiangmen...
2025-08-26 02:55
2259
Neopharma Technologies and Orient Gene Partner to Digitize Healgen® Drug Test Portfolio Globally with NEOVAULT®
Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 /PRNewswire/ -- Neopharma Technologies Limited ("Neopharma") today announced it hasentered into a global software licensing and collaboration agreement with Zhejian...
2025-08-26 02:10
1507
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390....
2025-08-25 21:18
2880
Everest Medicines Announces Participation in September Investor Conferences
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fin...
2025-08-25 20:57
1651
Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial
NANJING, China, Aug. 25, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data.This milestone endows...
2025-08-25 18:27
1754
Week's Top Stories
Most Reposted
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 274 media titles]
2026-01-01 10:00
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 260 media titles]
2025-12-29 14:27Most Read
POGMENT Biomimic Collagen Reacquired Recognition, Founder Appointed as Industrial Mentor for Master's Students at East China Normal University, Awarded 2025 Innovation Leadership Award
2025-12-31 17:21
5138
